Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Pedersen

Showing results (201-210 of 209) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 209 results.
Molecular Cancer Therapeutics|August 13, 2017
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple MechanismsMichael M Grandal, Serhiy Havrylov, Thomas T Poulsen, et al.
Nature|August 12, 2016
Postglacial viability and colonization in North America's ice-free corridorMikkel W Pedersen, Anthony Ruter, Charles Schweger, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Cancer Discovery|May 13, 2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal CancerRodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
JAMA Oncology|February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical TrialClara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
British Journal of Cancer|May 9, 2013
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancerB Burford, A Gentry-Maharaj, R Graham, et al.
Nature|September 17, 2020
Population genomics of the Viking worldAshot Margaryan, Daniel J Lawson, Martin Sikora, et al.
Nature|March 12, 2021
Author Correction: Population genomics of the Viking worldAshot Margaryan, Daniel J Lawson, Martin Sikora, et al.
Pageof 21

Showing results (201-210 of 209) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 209 results.
Molecular Cancer Therapeutics|August 13, 2017
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple MechanismsMichael M Grandal, Serhiy Havrylov, Thomas T Poulsen, et al.
Nature|August 12, 2016
Postglacial viability and colonization in North America's ice-free corridorMikkel W Pedersen, Anthony Ruter, Charles Schweger, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Cancer Discovery|May 13, 2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal CancerRodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, et al.
Science Translational Medicine|August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotypeBarbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
JAMA Oncology|February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical TrialClara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
British Journal of Cancer|May 9, 2013
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancerB Burford, A Gentry-Maharaj, R Graham, et al.
Nature|September 17, 2020
Population genomics of the Viking worldAshot Margaryan, Daniel J Lawson, Martin Sikora, et al.
Nature|March 12, 2021
Author Correction: Population genomics of the Viking worldAshot Margaryan, Daniel J Lawson, Martin Sikora, et al.
Pageof 21